Jazz Pharmaceuticals plc (JAZZ) Earnings History
Annual and quarterly earnings data from 2005 to 2025
Loading earnings history...
JAZZ EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
JAZZ Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 88.2% | 5.3% | -8.3% |
| 2024 | 89.0% | 17.6% | 13.8% |
| 2023 | 88.6% | 15.1% | 10.8% |
| 2022 | 85.2% | -1.8% | -6.1% |
| 2021 | 85.8% | 5.5% | -10.6% |
Download Data
Export JAZZ earnings history in CSV or JSON format
Free sign-in required to download data
Jazz Pharmaceuticals plc (JAZZ) Earnings Overview
As of May 6, 2026, Jazz Pharmaceuticals plc (JAZZ) reported trailing twelve-month net income of $29M, reflecting -167.5% year-over-year growth. The company earned $0.45 per diluted share over the past four quarters, with a net profit margin of -8.3%.
Looking at the long-term picture, JAZZ's historical earnings data spans multiple years. The company achieved its highest annual net income of $560M in fiscal 2024.
Jazz Pharmaceuticals plc maintains positive profitability with a gross margin of 88.2%, operating margin of 5.3%, and net margin of -8.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including SUPN (-$29M net income, -5.4% margin), PCRX ($9M net income, 1.0% margin), INVA ($271M net income, 63.8% margin), JAZZ has room to improve margins relative to the peer group. Compare JAZZ vs SUPN →
JAZZ Earnings vs Peers
Earnings metrics vs comparable public companies
JAZZ Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$356M | -163.6% | $224M | $-5.84 | -8.3% | 5.3% |
| 2024 | $560M | +35.0% | $717M | $8.65 | 13.8% | 17.6% |
| 2023 | $415M | +285.1% | $579M | $6.10 | 10.8% | 15.1% |
| 2022 | -$224M | +31.9% | -$66M | $-3.58 | -6.1% | -1.8% |
| 2021 | -$329M | -237.9% | $170M | $-5.51 | -10.6% | 5.5% |
| 2020 | $239M | -54.4% | $378M | $4.22 | 10.1% | 16.0% |
| 2019 | $523M | +17.1% | $532M | $9.09 | 24.2% | 24.6% |
| 2018 | $447M | -8.4% | $615M | $7.30 | 23.6% | 32.5% |
| 2017 | $488M | +22.9% | $529M | $7.96 | 30.1% | 32.7% |
| 2016 | $397M | +20.4% | $592M | $6.41 | 26.7% | 39.8% |
Full JAZZ Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See JAZZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JAZZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare JAZZ vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonJAZZ — Frequently Asked Questions
Quick answers to the most common questions about buying JAZZ stock.
Is JAZZ growing earnings?
JAZZ EPS fell to $0.45, with earnings declining -167.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $29M.
What are JAZZ's profit margins?
Jazz Pharmaceuticals plc net margin is -8.3%, with operating margin at +5.3%. Below-average margins reflect competitive or cost pressures.
How consistent are JAZZ's earnings?
JAZZ earnings data spans 2005-2025. The declining earnings trend is -167.5% YoY. Historical data enables comparison across business cycles.